Afrezza

Peptide

Approvedregulatory verdict

Evidence outlook

Approved: Type 2 Diabetes, Type 1 Diabetes

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (13)
Type 1 Diabetes
NCT00308308 · Mannkind Corporation
2006-02 – 2008-08 · Diabetes, Type I
What this study did
Type 2 Diabetes
NCT03324776 · Model Clinical Research LLC
2017-10-16 – 2020-06-10 · Type2 Diabetes
What this study did
NCT00642616 · Mannkind Corporation
2009-03 – 2014-11 · Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Moderate Chronic Obstructive Pulmonary Disease, Asthma
What this study did
NCT01196104 · Mannkind Corporation
2010-09 – 2012-03 · Type 2 Diabetes
What this study did
NCT00308737 · Mannkind Corporation
2005-06 – 2008-10 · Diabetes, Type 1, Diabetes, Type 2
What this study did
NCT00332826 · Mannkind Corporation
2006-06 – 2007-10 · Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Asthma
What this study did
Other / comorbidity
NCT00700622 · Mannkind Corporation
2008-05 – 2010-03 · Diabetes, Type 1
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT06535789 · Jaeb Center for Health Research
2025-06-02 – 2026-09-05 · Diabetes, Gestational, Pregnancy Complications, Glucose Metabolism Disorders, Glucose Intolerance During Pregnancy
What this study did
Phase 2 (10)
Type 1 Diabetes
NCT07224321 · Mannkind Corporation
2026-02-04 – 2027-09 · Type 1 Diabetes Mellitus
What this study did
NCT02527265 · Mannkind Corporation
2017-09-28 – 2020-06-25 · Type 1 Diabetes Mellitus
What this study did
Type 2 Diabetes
NCT00570687 · Mannkind Corporation
2007-09 – 2009-01 · Diabetes Mellitus, Type 2
What this study did
NCT00754624 · Mannkind Corporation
2004-05 – 2008-10 · Type 2 Diabetes Mellitus
What this study did
NCT00511732 · Mannkind Corporation
2004-06 – 2007-08 · Type 2 Diabetes Mellitus
What this study did
NCT00934414 · Mannkind Corporation
2004-08 – 2006-09 · Diabetes Type 2
What this study did
NCT00511602 · Mannkind Corporation
2003-12 – 2005-12 · Type 2 Diabetes Mellitus
What this study did
NCT00511719 · Mannkind Corporation
2004-02 – 2005-03 · Type 2 Diabetes Mellitus
What this study did
Phase 1 (12)
Type 1 Diabetes
NCT02485327 · Mannkind Corporation
2015-07 – 2015-11 · Type 1 Diabetes Mellitus
What this study did
NCT01544881 · Mannkind Corporation
2012-03 – 2013-01 · Type 1 Diabetes Mellitus
What this study did
Other / comorbidity
NCT03234491 · Yale University
2017-11-22 – 2019-07-22 · Post-Prandial Hyperglycemia, Post-Prandial Hypoglycemia
What this study did
NCT01982604 · Mannkind Corporation
2013-11 – 2014-08 · Healthy Volunteers
What this study did
NCT01902121 · Mannkind Corporation
2013-08 – 2014-08 · Healthy Volunteers
What this study did
NCT01490762 · Mannkind Corporation
2011-12 – 2012-07 · Healthy
What this study did
NCT01365117 · Mannkind Corporation
2011-01 – 2011-04 · Healthy Volunteers
What this study did
NCT00673621 · Mannkind Corporation
2008-05 – 2008-12 · Asthma, Diabetes Mellitus
What this study did
Phase 4 (6)
Type 1 Diabetes
NCT05904743 · Mannkind Corporation
2023-07-07 – 2024-06-24 · Diabetes Mellitus, Type 1
What this study did
NCT05243628 · Mannkind Corporation
2022-03-31 – 2022-10-17 · Type 1 Diabetes
What this study did
NCT03143816 · University of Colorado, Denver
2017-09-30 – 2018-01-31 · Diabetes Mellitus, Type 1
What this study did
Type 2 Diabetes
NCT04849845 · Mannkind Corporation
2021-04-09 – 2021-05-28 · Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
What this study did
NCT04125082 · Diabetes and Glandular Disease Clinic
2019-02-27 – 2020-03-15 · Type 2 Diabetes Treated With Insulin
What this study did
NCT03313960 · Informed Data Systems, Inc.
2017-10-05 – 2019-12-30 · Diabetes Mellitus, Type 2
What this study did
Early phase / not applicable (3)
Type 1 Diabetes
NCT01874392 · Sansum Diabetes Research Institute
2012-10 – 2013-06 · Type 1 Diabetes Mellitus
What this study did
Other / comorbidity
NCT06880835 · Jaeb Center for Health Research
2025-06-05 – 2026-12-31 · Diabetes Mellitus, Type 1
What this study did
NCT01459133 · South Orange County Endocrinology
2013-05 – 2014-10 · Diabetes
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Type 1 Diabetes: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Afrezza: this drugApprovedPeptideInsulinPartial signal
NCT04974528: HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. missed
NCT01445951: Change in HbA1c from baseline to week 24 (LS mean): Technosphere Insulin (Gen2 inhaler) plus basal insulin -0.21% vs insulin aspart plus basal insulin -0.40%; difference 0.19% (95% CI 0.02 to 0.36), inside the pre-specified non-inferiority margin of 0.4% (CT.gov posted analysis).
Insulin Aspart (NovoLog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (Fiasp)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Degludec (Tresiba)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Detemir (Levemir)
ApprovedUS marketing discontinued
PeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glargine (Lantus)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glargine (Basaglar)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glargine (Toujeo)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glulisine (Apidra)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin HumanApproved—Insulinnot yet gradedNo reviewed efficacy summary in this indication
Insulin Lispro (Humalog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Lispro (Lyumjev)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin NPH (Humulin N)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Pramlintide (Symlin)
ApprovedUS marketing discontinued
PeptideAmylin receptornot yet gradedNo reviewed efficacy summary in this indication
CadisegliatinPhase 3Small moleculeGlucokinasenot yet gradedNo reviewed efficacy summary in this indication
Sotagliflozin (Inpefa)Phase 3Small moleculeSGLT1/2 (dual)not yet gradedNo reviewed efficacy summary in this indication
ZimislecelPhase 3Cell therapyPancreatic islet cells (VX-880 is a stem cell-derived therapy, not a small molecule drug), Pancreatic islet cell replacementnot yet gradedNo reviewed efficacy summary in this indication
IcovamenibPhase 2Small moleculeMeninnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Afrezza to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
March 2027 (1)
Phase 2Type 1 DiabetesRecruiting
Est. primary completion 2027-03 · NCT07224321 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

29 May 2026ApprovalFDA approves Afrezza for pediatric use (ages 6+)
US, FDA · Source ↗